secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001628280-22-022333
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance
--------------------------------------------------------------------------------

- Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.
- GAAP net loss of ($8.0M) vs ($10.8M) in Q2 2021; diluted loss per share ($0.11) vs ($0.10).
- Adjusted EBITDA of $22.9M vs $19.9M YoY; Non-GAAP EPS $0.10 vs $0.11.
- FY22 guidance narrowed: net sales $547.5-562.5M (mid-point unchanged); adjusted EBITDA $94-104M.
- Discontinued MOTYS development; completed CartiHeal acquisition on July 12, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/0001628280-22-022333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/bvs-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-022333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer